A medication designed to assist people living with multiple sclerosis in walking is now accessible through the NHS in England. Known as fampridine, this drug functions as a signal booster, enhancing nerve impulses to support movement and personal independence.
Multiple sclerosis occurs when the immune system degrades myelin, the protective sheath surrounding nerve cells, which disrupts the body’s ability to transmit electrical signals for muscle control. Clinical studies indicate that roughly 40 percent of participants experienced improved walking speed and endurance while using the drug.
Aysen Slack, a 65-year-old from Eastbourne, previously self-funded the treatment but was forced to stop due to the high financial burden. She expressed that the NHS decision is welcome news, noting that even minor improvements in mobility significantly alter daily life. Approximately 5,000 people in England are expected to meet the criteria for the treatment annually, with patients undergoing a one-month trial to confirm clear benefits before continued prescription.
Health officials and advocacy groups, including the MS Society, have praised the development. They highlight that restoring mobility allows patients to engage more freely with their surroundings and maintain their independence. While the drug was previously deemed not cost-effective for NHS use in England, it has already been available to patients in Scotland, Wales, and Northern Ireland.
